4.7 Article

Passive immunotherapy for Middle East Respiratory Syndrome coronavirus infection with equine immunoglobulin or immunoglobulin fragments in a mouse model

Journal

ANTIVIRAL RESEARCH
Volume 137, Issue -, Pages 125-130

Publisher

ELSEVIER
DOI: 10.1016/j.antiviral.2016.11.016

Keywords

Middle East Respiratory Syndrome coronavirus; Equine immune serum; Immunoglobulin; F(ab ')(2) fragment; Animal model

Funding

  1. National Key RD program [2016YFC1200902]
  2. Ministry of Science and Technology of China [2014ZX09102044-007]
  3. Municipal Healthcare Joint-Innovation Major Project of Guangzhou [201604020011]
  4. State Key Laboratory of Respiratory Disease
  5. National Institutes of Health

Ask authors/readers for more resources

Middle East Respiratory Syndrome (MERS) is a highly lethal pulmonary infection caused by a coronavirus (Coy), MERS-CoV. With the continuing spread of MERS-CoV, prophylactic and therapeutic treatments are urgently needed. In this study, we prepared purified equine F(ab')(2) from horses immunized with MERS-CoV virus-like particles (VLPs) expressing MERS-CoV S, M and E proteins. Both IgG and F(ab')(2) efficiently neutralized MERS-CoV replication in tissue culture. Passive transfer of equine immune antibodies significantly reduced virus titers and accelerated virus clearance from the lungs of MERS-CoV infected mice. Our data show that horses immunized with MERS-CoV VLPs can serve as a primary source of protective F(ab')(2) for potential use in the prophylactic or therapeutic treatment of exposed or infected patients. (C) 2016 Published by Elsevier B.V.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available